P Coplan

Summary

Affiliation: Merck Research Laboratories
Country: USA

Publications

  1. ncbi request reprint Incidence and hospitalization rates of varicella and herpes zoster before varicella vaccine introduction: a baseline assessment of the shifting epidemiology of varicella disease
    P Coplan
    Merck Research Laboratories, Blue Bell, PA 19422, USA
    Pediatr Infect Dis J 20:641-5. 2001
  2. ncbi request reprint Incidence of myocardial infarction in randomized clinical trials of protease inhibitor-based antiretroviral therapy: an analysis of four different protease inhibitors
    Paul M Coplan
    Department of Epidemiology, Merck Research Laboratories, West Point, Pennsylvania 19486, USA
    AIDS Res Hum Retroviruses 19:449-55. 2003
  3. ncbi request reprint Modeling the long-term outcomes and costs of HIV antiretroviral therapy using HIV RNA levels: application to a clinical trial
    J Cook
    Merck and Co, Inc, Whitehouse Station, New Jersey 08889, USA
    AIDS Res Hum Retroviruses 15:499-508. 1999
  4. ncbi request reprint Fat redistribution in indinavir-treated patients with HIV infection: A review of postmarketing cases
    J O Benson
    Merck and Company, Inc, West Point, Pennsylvania, USA
    J Acquir Immune Defic Syndr 25:130-9. 2000
  5. ncbi request reprint Epidemiology of bacterial meningitis among children in Brazil, 1997-1998
    D P Weiss
    Department of Epidemiology, Merck Sharp and Dohme Research Laboratories, West Point, Pennsylvania, USA
    Rev Saude Publica 35:249-55. 2001

Collaborators

Detail Information

Publications5

  1. ncbi request reprint Incidence and hospitalization rates of varicella and herpes zoster before varicella vaccine introduction: a baseline assessment of the shifting epidemiology of varicella disease
    P Coplan
    Merck Research Laboratories, Blue Bell, PA 19422, USA
    Pediatr Infect Dis J 20:641-5. 2001
    ..We report on a baseline assessment of the age-specific incidence and hospitalization rates of varicella and herpes zoster that was conducted before vaccine introduction...
  2. ncbi request reprint Incidence of myocardial infarction in randomized clinical trials of protease inhibitor-based antiretroviral therapy: an analysis of four different protease inhibitors
    Paul M Coplan
    Department of Epidemiology, Merck Research Laboratories, West Point, Pennsylvania 19486, USA
    AIDS Res Hum Retroviruses 19:449-55. 2003
    ..Although studies with a longer duration of PI therapy are in progress to assess whether a later increase in MI incidence occurs, our analysis did not demonstrate a dramatic increase in MI risk during the first year of PI therapy...
  3. ncbi request reprint Modeling the long-term outcomes and costs of HIV antiretroviral therapy using HIV RNA levels: application to a clinical trial
    J Cook
    Merck and Co, Inc, Whitehouse Station, New Jersey 08889, USA
    AIDS Res Hum Retroviruses 15:499-508. 1999
    ..At 20 years, the incremental cost per life-year gained by adding IDV to a ZDV+3TC regimen was estimated at $13,229, which is well within the range of other widely accepted medical interventions...
  4. ncbi request reprint Fat redistribution in indinavir-treated patients with HIV infection: A review of postmarketing cases
    J O Benson
    Merck and Company, Inc, West Point, Pennsylvania, USA
    J Acquir Immune Defic Syndr 25:130-9. 2000
    ....
  5. ncbi request reprint Epidemiology of bacterial meningitis among children in Brazil, 1997-1998
    D P Weiss
    Department of Epidemiology, Merck Sharp and Dohme Research Laboratories, West Point, Pennsylvania, USA
    Rev Saude Publica 35:249-55. 2001
    ....